CM Hospitalar S/A (BVMF:VVEO3)
Brazil flag Brazil · Delayed Price · Currency is BRL
0.5600
+0.0200 (3.70%)
At close: Nov 17, 2026
← View all transcripts

Earnings Call: Q3 2026

Nov 11, 2026

Summary

Q3 revenue rose 7.8% YoY, led by 18.9% growth in hospitals and clinics, while adjusted EBITDA grew 13.1%. A BRL 867 million capital increase and debt reduction strengthened the balance sheet, though fire disruption and near-term cost and tax volatility remain.

Operator

Good morning, and thank you for waiting. Welcome to Viveo's third quarter earnings release video conference of third quarter of 2026. I would like to point out that those of you who need simultaneous interpretation, we have this tool available on the platform. In order to access it, just click on the interpretation button through the globe icon at the bottom of the screen and choose the language of your preference. For those of you who are listening the video conference in English, there is an option to mute original audio in Portuguese by clicking on mute original audio. We inform you that this video conference is being recorded and will be made available on the company's IR site, www.viveo.com.br/ir, where the complete material for our earnings results announcement is going to be available, and you can also download the presentation from the chat icon.

During company's presentation, all participants will have their microphones disabled, and we will then begin with the Q&A session. In order to ask your questions, click on the Q&A icon at the bottom of your screen and write your question and your company's name to join the queue. Upon being announced, a request to activate your microphone will appear on the screen in order for you to ask your question, and we advise and ask you for questions to be asked all at once. We also would like to emphasize that the information contained in this presentation and any statements that may be made during the video conference related to business perspectives, projections, financial goals of Viveo constitute beliefs and assumptions of company's management, as well as the information currently available.

Forward-looking statements are not guarantees of performance, but rather involve risks, uncertainties, and assumptions as they refer to future events and therefore depend on circumstances that may or may not occur. Investors should understand that general economic conditions, market conditions, and other operating factors may affect Viveo's future performance and lead to results that may differ materially from those expressed in such forward-looking statements. This morning, we count on Mr. André Clark, the CEO, Frederico Oldani, Vice President and financial manager, and other directors. Now, I'd like to give the floor to Mr. André Clark, who will begin the presentation. Dr. André?

André Clark
CEO, CM Hospitalar

Good morning, ladies and gentlemen. Thank you very much for your attention and for your presence, for attending this call. May I proceed? Our apologies. We had a minor glitch here with our audio. Good morning, ladies and gentlemen. Thank you very much for your attention and for attending this earnings release call for the third quarter of 2026, and we have a set of important messages to offer to you today. Next slide, please. Well, this quarter is marked by the completion of the very successful financial restructuring of our company. Again, obviously counting on the trust of our creditors and the capital market as a whole, we can see our EBITDA and indebtedness, and that is bringing the company to a rather stable condition with a down of 1.66x over 12 months.

We can see there's a BRL 867 million capital increase, and also the reduction of the gross debt and the capitalization of the debentures receivables contributing to a reduction of the gross debt and a strong participation in the transaction. Well, this was a very, very successful process. Well, for the next steps, as a result of a lot of effort and positive results, especially when dealing with high-cost medicaments, we have been having great results. Now, we will continue restructuring our business, and we will do the business review, initiatives to adapt the operating models, review commercial terms, prioritizing the profitability in the consumers' products and pharmaceutical compounding operations in order to really strengthen our reliability.

Given the environment of the oncology market restructuring, we are benefiting from this opportunity in order to restructure the pharmaceutical compounding operations, better models, how to better serve our clients, changing the supply strategies, and both operational and regulatory aspects of our operations. With a highlight to the operations in Porto Alegre. In the second quarter of 2026, we have launched some initiatives with a lot of focus on profitability and operational efficiency in long term.

We sort of fixed the main engine of, and the main flag of this company. This is the core of this company, the materials. With that said, we are now putting together, and obviously always working with continuous improvement and with our businesses and trying to just level up the playing field. During the first half, the second half, we had an important event, which was the fire at the Cremer facility. No victims, no one got hurt, and the firefighting procedures were very effective with local authorities, and it was a very successful operation. Fire was put out immediately after it started, and especially, if we talk about the medical adhesive tapes and the Micropore tapes and others, this was very much affected. In terms of our inventories, raw materials and on-site inventories were preserved and with very little damage.

Also the facilities as a whole have been mostly preserved. We are working very hard to work with the operational recovery. The financial exposure is of 1.7% of the net revenue, and the gross profit is approximately BRL 7 million a month. We have a whole set of measures which are being put forth in order for us to resume the operations as quickly as possible. We have two production lines, one which was left intact, and we are now replanning the whole process. Obviously, we will have to work with the supply chain, and this reorganization is underway, but we hope to have this fixed very, very soon. For the third quarter, the one highlight I think we should pay attention to with regards to the current challenges are really the oil and the variability on some supply products with price oscillation.

The second point that we could highlight is the high interest rates, that continued pressure in the net financial results, and the tax reform. We have to be really adaptive. Given the uncertainty, the regulatory uncertainties, the working capital, the players are definitely behaving somewhat different. They are having issues in repricing their products in the turn of the year. All those elements together have been leading to some confusion in the planning, but they are part of the macroeconomic scenario, and it very soon should converge to a stable situation. We had definitely the beginning of the second half of the year somewhat turbulent, and we also had an important element here related to the occupational regime, reduction of working hours, the 6x1 schedule change. There was a gradual implementation with some impacts concentrated in the operations, particularly in the manufacturing.

Obviously, we have mitigation measures that have been clearly defined, like adjusting the work schedules and the shifts, optimizing staffing, reducing overtime, and improving productivity, and assessing the price pass-throughs for manufactured products. This was not our sole privilege. This affected the whole sector, and we really call your attention to the volatility of this environment. Well, some important highlights here that deserve some attention before giving the floor to my dear friend, the CFO of our company. Our net revenue grew over the Q3 around 7.8%, if compared to last year, and 4.3% in the year-to-date, supported by the growth in the high-cost medications in hospital and clinic sector, and showing the full restructuring of this business. The year-to-date profitability indicators have improved. They continue to improve, as a matter of fact, with gross margins of 15.7%, and we have been focusing on continuous improvement.

This, little by little, is going to improve, and we have this 1% increase in the adjusted EBITDA margin to 7.1% in our cash conversion cycle, excluding receivables, and ended the third quarter in 54 days, the best result of the year, and eight days below the same period of last year. So, very important results have been accomplished. Anyway, now I'd like to give the floor to Freddy so that he can tell us more about the financial performance.

Frederico Oldani
VP and Financial Manager, CM Hospitalar

Good morning. I'm starting here on slide number nine. The net revenue reached BRL 3.55 billion over the quarter, as mentioned, a 7.8% growth vis-à-vis to the same period last year, and with the year-on-year accurate results of 4.3%. It's important to highlight the performance of each one of the segments that we operate. Now moving to slide number 10, and we check here the performance per segment, we can see the very, very strong performance of hospitals and clinics sector, obviously pushed by the drive in high-cost medication, and 18.9% in the quarter. So really outstanding, exceeding our expectations. After all the adjustments that have been made throughout the year of 2025 and in the beginning of 2026, that basically demonstrates that post-contract renegotiation, and this, the third quarter, is a quarter where all contracts have been revised, amended, renegotiated.

So we've accomplished our goals of additional reduction of working capital and other improvements on contract conditions, and we can follow seeing a very robust demand in this segment. Now, on labs and vaccines, we've had a performance that was somewhat opposite to that. As we mentioned, in the vaccines, this was the main flag on the turnover reduction of the segment. So we had three vaccines that were very, very relevant ones, and those were the very important contributions, the main contributions for the growth in 2025, and was incorporated for 2026. Well, it's not that it's changed the demand, but rather the demand started to be supplied by the public sector, and that naturally drained and exhausted the role of the private sector within the segment. But other than that, we don't really see major structural changes within the vaccine sector.

Well, from time to time, we might have vaccines that are incorporated, and we might see a temporary displacement, but our view on the vaccine sector is that we have some innovations that have happened and will continue to happen over the next years. Now, on the lab sector, there was a punctual event in the supply of reagents in this half year. This is being stabilized throughout Q3, and this is caused by some regulatory changes in the imports, proceedings of those products that have led to some shortages throughout Q3. This is absolutely contextual and will soon be normalized. On consumer products and the net revenue, we had a slight drop, 4.7% drop. As André mentioned, we have restructured the sector quite dramatically. We are reviewing contracts, we are working on prices and portfolios.

It is a full review that should very soon, as of the beginning of next year, generate results. Consumer products will definitely help differently from the distribution, because over the last years, we have actually focused a lot of energy in improving the business model. We are now going to develop the very same type of work, very much focused on consumer products. Obviously, we have other elements, but consumer products is where we have effective actions being taken. We have the pricing project in an advanced phase, and many other fronts that have been implemented in order to improve our position within the consumer products sector. On services, we also observed some retraction throughout this quarter, and the main factor we could point out, as André mentioned, is basically caused by the review of our Insuma commercial model.

Obviously, the Porto Alegre suspension of operations had a role to play. We not only had operational improvements and regulatory changes have been partly responsible for this suspension, and we are still studying how we are going to resume and under what circumstances we would resume this operation throughout the year of 2027. When we check the performance, we have substantial differences when we check in the segment-per-segment basis. Now, proceeding to the gross profit comments. On our gross profit, I mean, the consolidated gross margin went down a little bit and reached 14.6%. There was a pressure here, not necessarily by the drop on the margins.

We can see that we have improved the margins in most of the segments, but given the growth, which was remarkable in the hospitals and clinic segment, the fact that that growth was quite remarkable when we sum up the average, when we average it up, it ends up neutralizing. When we see at a channel-per-channel basis, we can see that it is really remarkable with a nice expansion tendency in all of them.

The adjusted EBITDA went up 13.1%, and with a good improvement, the final figure is 6.4% with a good progress vis-à-vis to the same period of last year. We can see the operational efficiency considerably improved over the last quarters. In our view, this last third Q was a quarter that was somewhat similar to the previous ones, but that once again demonstrates that we are on the right track, that the company has adopted the right strategy, although we acknowledge that we are still far from our aspiration. We still have some segments that are underperforming vis-à-vis to our intention. Despite the hard work over the last years, we naturally see that there are opportunities for us to improve our performance. The message is our result is okay, but far from what we can deliver over the coming years. Now, proceeding with the financial results.

In the net financial results, we had an increase vis-à-vis to last year, both on the quarter as on the year. But it's worth mentioning two relevant elements here that have reduced the financial expenditure. The first one was the default. In the first quarter, we have reverted this. We have this reversal of the default-related charges, and that had a positive impact on the net financial results of the year of 2025. We also mentioned that we had relevant amounts spent on the purchase of the debentures, especially in the third quarter of last year, what makes this comparison somewhat skewed. The data end up being not fully comparable.

It's interesting to highlight, to see that the financial result was not impacted by the capital increase, and that despite we did a capital increase along the quarter, we will have some adjustments on the financial expenses because of the debt reduction. As of the fourth quarter, we will open with a substantially smaller debt if compared to what happened in the third quarter. Having said that, our net result was of a loss of BRL 75 million in the third quarter, but that does not reflect all the changes that were done on the equity structure that should help our net financial results as of the coming quarters. Now on the cash flow, our free cash flow was quite positive, up to 51.4% on a year-on-year, and it's a little bit smaller than third quarter of last year, which was dramatically affected by the contract negotiation.

We had relevant changes that impacted this result, and this year we had substantially smaller reductions this year if compared to last year. But we understand that BRL 150 million is a robust figure, pretty much aligned to and compatible to our current cash generation capacity. So we have 51% above the same period of 2025. Now, on our cash conversion cycle, that was quite positive, I should say. We've accomplished here 46 days. Even if we consider the receivables days, this is substantially smaller if we compare it to what we had in the third quarter of last year. This is very positive, especially if we talk about the working capital over net revenue, and it's 19.4%. So we're still vis-à-vis to 18% this year. So, a difference if compared to the present.

Anyway, when we started to implement those changes in the company two years ago. Indebtedness, and I think that the main point here of indebtedness, this is related to a capital increase, and we have important remarks here both on the gross debt and on the net debt. So within the third quarter, we had BRL 395 million, and it went from BRL 439 million to BRL 328 million, not to mention the 100% of equity increase that has been confirmed. In the last column here, when we see what would be the leveraging with 100% of the capital increase, our cash covenant would be actually below 3 times, and what would give us a lot of leeway with regards to the renegotiated covenants together with our creditors in the first quarter of this year.

So that basically makes us quite confident in working with in navigating through the next quarters. I would say that those were the main points vis-a-vis to the performance of this quarter. Now, let's open to the Q&A session.

Operator

We will now start with the questions- and- answers session, and we would remind you that in order to ask questions, you must click on the Q&A icon at the bottom of the screen to join the queue. Once you are announced, a request to activate your microphone will appear on the screen. Please make sure you turn on your mic to ask your question. We kindly request that all the questions are asked all at once. Our first question comes from Mr. Ezi Croker from Bank of America. Please proceed.

Ezi Croker
Analyst, Bank of America

Good morning. Thank you for accepting our question. The first is with regards to EBITDA margin. What can we expect in the future? Can we expect efficiency gains coming from contract renegotiation, or can we see a margin flattening in the short and mid-term due to the impact of the fire in Blumenau plant? Also with regards to the 6x1 working shift. The other question is on the cash conversion cycle, especially on the receivable side. I just would like to understand whether this is an ideal level, or do we have any other improvements to be relished in this part? Is this improvement in the receivables related to the mix change with the highest voice of hospitals and clinics sector?

Frederico Oldani
VP and Financial Manager, CM Hospitalar

Yes. This is Fred speaking. Well, thank you for your question. With regards to the margins, yes, they are as deeply influenced by the mix. In the fourth quarter, we should have some effect related to that event, the fire event, since that plant, the facilities affected have a gross margin which is substantially higher than the average of the company. On the other hand, as you might have noticed, we have insurance, and the insurance partly covers. Our insurance covers not only the facilities, but also the lost profit. So we have something like BRL 15 million that we don't know exactly whether this is going to be acknowledged and will in the fourth quarter, or if this is going to carry over for next year.

But on one hand, we'll have the margin reduction given the reduction on the volume of adhesives, but also we'll have the insurance on the lost profits that we don't know exactly when this is going to be acknowledged. Definitely, when we look on the short term, as André mentioned, we believe that there are some remarkable pressures to be mitigated here in the 6x1 working shift, the raw materials prices, and so on. But we do have a lot of room to proceed with higher margins than the ones that we are delivering now, despite those minor effects that we might see on the very short term. On the working capital and the receivables, the second quarter was when we finished doing the adjustments here on the contracts.

We had contracts that before 2025, we would have a maturity of 120 days, and on the renegotiation of last year, we basically merged all of them to 75-90 days, and in the following quarter, everything to 60 days. So, I would say that our homework has been done. We do not expect major changes, although there are some seasonal elements here that might make a difference. I would say that the objectives that we had accomplished in terms of maturity and deadlines changes, we have just closed the cycle in this quarter. Thank you.

Ezi Croker
Analyst, Bank of America

Thank you very much.

Operator

Our next question comes from Diego Vilela from JPMorgan.

Diego Vilela
Analyst, JPMorgan

Hello, good morning. Thank you for the call. My question is about the tax reform. Let me hear from you how it is that you have been getting braced for this change, and in many aspects, systems, operational, if the company could run on the new standards, and how do you see the suppliers on this agenda? That is it. That is what I have for now. Thank you.

André Clark
CEO, CM Hospitalar

Well, let me start, and maybe Fred can add. January 2027, we have the beginning of the CBS and the regulation or the regulatory details. The details are still being defined, and that will generate short-term effects, inventory, turnover, supply, conditions. This will naturally generate some turbulence on this aspect, but we are very much prepared for 2027 from the IT and our systems, and also internal readiness. We are quite mature in that aspect, and we are ready to turn the key in January. A very important work with the suppliers has been done in terms of repayment and a couple of other rules, both on the vendors and in the manufacturers. The tax reform will have an impact on the industrial operations and on the distribution operations, and it is not fully clear what are the effects.

Basically because this is a play-by-year situation, but this is definitely gigantic. It is multidisciplinary. All businesses are reviewing their chains, both upstream and downstream, and that has important opportunity changes on how the margins are defined, how we operate, and so on. The tax reform in its entirety is quite transformational to our business and logistics transformation. That will change dramatically the way we operate on this market. All that obviously is a huge project. We have more than 30 leaders directly involved in all sectors, all fronts, all businesses. It is a huge transformation and definitely with suppliers. Now let me give the floor to Fred now, and a lot of the coordination is under him.

Frederico Oldani
VP and Financial Manager, CM Hospitalar

André has basically mentioned here the main points, and let me just make a few comments on the potential effects on the short term that we see on the fourth quarter. I would say the main effect for the fourth quarter is related to products that will have price changes due to either an increase or decrease tax burden, especially on the turn of the year. Today we have products that have PIS or COFINS types of taxes or CRAT and DABT. We will have those regimens changing, and we have products that may be cheaper, some others might be more expensive. Products that would be cheaper in January because of the new tax regimen. We see players that are changing their inventories strategies for next year, and we also see the opposite in we have clients who want to do differently.

As André said, we are on both ends, so we have this negotiation both upstream and downstream, as he mentioned. But none of that are recurrent effects. This is going to be a one-off event, and we'll basically displace procurement from the third and fourth quarters because of the either higher or lower CBS brackets and their differences vis-a-vis to the current tax. Especially on the medicaments that haven't been fully defined which ones are going to be exempt and others that will still have the 60% tax burden. That might generate effects. The industry will obviously have to operate changes, the suppliers will operate changes, and the clients themselves will have to accommodate for the turn of this year.

Diego Vilela
Analyst, JPMorgan

Thank you, guys.

Operator

Once again, let us remind you that in order to ask your questions, you can click on the Q&A icon and have your name and your company's name and to be queued.

André Clark
CEO, CM Hospitalar

We have two questions here. The first is about the effect of the equity increase on our results. I would say that this should have an effect of BRL 135 million at a yearly basis. This is our expectation. Of course, that will depend on the This has been calculated based on the current interest rates. We could also add the competition element. It's a highly dynamic market, especially in oncology. We have new players coming in, and we also have old players who are getting out of this game with the theories and hypotheses that did not materialize. It's a very dynamic market, especially for high-cost medicaments, certainly materials. Here, the tax reform on the long run will definitely have an impact on this scenario, in particular in the pursuit of efficiency and better margins and so on.

Now, on consumption, obviously, we have competition, and on consumer products, we will have a short-term effect, more on the short term rather than on the long term. From the competition perspective, we don't really see a huge change. What we have here are many different actions and significant actions of some health-related markets, the organizations, some switch on the players, some others are coming out of the business, some are coming in. But we are very important service providers, and we are doing our homework. We love healthy competition. Competition will always be there, but we don't really see a major competition effect happening at this point. It's pretty normal.

Operator

Next question comes from Mr. Marcio Osako from Bradesco BBI.

Marcio Osako
Analyst, Bradesco BBI

"Good morning, André. Good morning, Freddy. Actually, I have three questions. The first, if you could please explain a little bit better the service provision model change in oncology. The second is on medication. If you were not selling medicaments to some labs, and how much of the growth on this third quarter came from the resumption of the sales of medicaments with those labs that had their contracts reviewed? Then last, why is it that the recoverable tax line is consuming much more taxes than last year?"

Frederico Oldani
VP and Financial Manager, CM Hospitalar

Excellent questions, Marcio. Thank you. First of all, oncology. Let's put it like this. The way that the population is served here in Brazil is undergoing major changes given the circumstances that we can see through the media. Many of the players, they want to get the high-cost medication in accurate milligrams. Of course, that increases safety, but that jumps up to or steps up to a new level. We have oncology clinics that deliver the material with the patient's name ready to infusion in less than one hour at chair side. It is just in time. We will do much, much more than that because the demand is out there. The players are getting themselves reorganized, and those are very sensitive medications to be manipulated, and we obviously have to be very attentive to the safety issues.

It is an opportunity for us to completely rethink when, where, how the players want to play this game, how the insurance companies want to redefine, because the patient is out there, but the health insurances are obviously changing things, and also the value chain will obviously be subject to change. We are service providers in this field. It is a next mile of distribution. This is what we can do from the regulatory perspective together with the plant. On the medication, we have always been there with all the medicaments trying to supply. What is happening is that as we improved and enhanced our processes, that has increased. We have increased our scale towards all the big pharmas, especially in the high cost. This is a market that keeps on growing in two-digit rate or more in Brazil.

Our operational improvement from one side and financial and economic risks on the other side, accuracy, have less mistakes, integrity, quality of delivery, safety. Those are elements that have increased our participation on the high-cost drugs that have always existed. The great players, they need this to be delivered in hospitals. The hospitals, they pick their vendors, and we have been consistently chosen and selected in the space, gaining share, gaining credibility in an ever-growing market. This is the history, and that is behind our day-by-day in hospitals and clinics. We are becoming better in our core business, and this will definitely have an impact on the auxiliary services. With regards to what to expect, I would say that part of it is a natural consequence of this movement of medicament growth.

The main segment that generates credit accumulation is the medication one, despite we have consistently grown in this sector vis-à-vis to others. This is the main factor behind that. The second factor is the inventory movement if compared to last year. Last year, we were reducing our inventory, and that is another element that will reduce our balance. This year, despite having reduced in the number of days, our growth was stronger in the previous quarters, basically pushed by the medication. We have had the opposite effect, which was increased inventory and increased inventories within the segment that will generate more credit. Those are the two effects.

Marcio Osako
Analyst, Bradesco BBI

Okay, thank you.

Operator

We are now closing the Q&A session, and we would like to give the floor to Mr. André Clark for the final remarks.

André Clark
CEO, CM Hospitalar

Once again, thank you very much for attending our earnings results. We hope to be on the right track, and we are always trying to be very much responsibly accountable for the continuous improvement, doing our step-by-step work, and being better at every day. Having structured our equity structure, that brings the operational decisions to a much more rational level that allows us to operate the company much more efficiently. We are basically reformulating the way we operate some of the businesses, the increased profitability, and broader margins and capital efficiency. Thank you very much. We will continue with this approach of reducing indebtedness, improving EBITDA, and improving the company's operations. Thank you very much once again.

Operator

Our earnings results call relative to the third quarter of 2026 is now closed. The investor relations department is at your service to answer questions. Thank you very much to all participants, and wishing you all a great day.